John N. Weinstein, M.D., Ph.D., chair of Bioinformatics and Computational Biology and professor of Systems Biology at The University of Texas MD Anderson Cancer Center, has been elected to the 2025 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of decades of combined laboratory and computational work pioneering multi-omic molecular profiling, including the introduction of new laboratory techniques, clustered heat maps, and early innovations in artificial intelligence for cancer drug discovery.

Lung cancer (LC) remains the leading cause of cancer-related deaths worldwide, characterized by high mortality rates and limited treatment options. MicroRNAs (miRNAs) are critical regulators of gene expression and play significant roles in the development of LC. This review aimed to provide a comprehensive analysis of oncogenic miRNAs involved in LC, focusing on their dysregulation, functional roles, and potential implications for diagnosis and therapy. In this review, we collected data from published literature, specifically selecting English articles closely related to the topic. We conducted a thorough review of studies published between 2013 and 2023, utilizing prominent academic databases such as PubMed, Scopus, and Google Scholar to gather relevant data. Our investigation highlights several oncogenic miRNAs that have been shown to play critical roles in lung cancer biology, including miR-9-5p, miR-21, and miR-31. These miRNAs are known to facilitate various key processes, such as tumor cell proliferation, enhanced migratory capabilities, and the development of resistance to chemotherapeutic agents. Additionally, miRNAs present significant diagnostic and therapeutic potential. In conclusion, the unique roles and regulatory networks of miRNAs in LC warrant extensive further research. Further research is essential to uncover the complex networks of miRNAs and to develop innovative miRNA-based therapies for lung cancer.

Cambridge, MA, April 18— Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is proud to announce  Pharma.AI Day 2025, the brand-new quarterly update series for Pharma.AI, scheduled on April 24, 10:00-11:00 AM EST. Register here to join Alex Zhavoronkov PhD, Founder and CEO of Insilico Medicine, and get a deep dive into a series of AI breakthroughs and new product demos.

An Osaka Metropolitan University-led research team conducted a meta-analysis of the diagnostic capabilities of generative AI in the field of medicine using 83 research papers.

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection with 99.9% to 100% efficacy and could dramatically lower infection rates worldwide.